The Trump administration is weighing how to respond to a court ruling on vaccine policymaking, a decision that could come ...

Today's biotech news includes the Medicare director offering a tempered view of TrumpRx and high-dose Wegovy getting an FDA ...

In today's Morning Rounds newsletter, the highlights from #STATBreakthrough, a ruling against Kennedy’s gender-affirming care ...

This week on "The Readout LOUD," a conversation with biotech "godfather" Stelios Papadapolous live from #STATBreakthrough.

STAT interviews with 30 respondents brought the unmistakably human impacts of federal science policy into sharp focus. Here are three of those stories.

A group of autism scientists kicked off efforts Thursday to influence Congress, and the research agendas of private ...

Congress must fix the No Surprises Act before it bankrupts patients and employers, James Gelfand and Patricia Kelmar write.

The farm bill shows politicians catering to the agriculture industry risk losing the support of MAHA while running afoul of ...

What's changed now is that there's a view in this administration that everything is political,” said Robert Califf, former ...

And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about ...

Following successful appeals from drugmakers, the U.K. is taking another look at whether two new Alzheimer's drugs can be considered cost-effective.

Looking to bolster its pipeline, Novartis is buying a breast cancer drug candidate for $2 billion from Delaware-based Synnovation Therapeutics.